MedTrace Logo

ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis

NCT04522310 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183

Last updated 2021-08-05

No results posted yet for this study

Summary

COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.

Conditions

  • Covid19

Interventions

OTHER

MR-Pro-ADM

Dosage of MR-pro-ADM

Sponsors & Collaborators

  • Centre Hospitalier de Lens

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2021-02-28
Completion
2021-05-29

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04522310 on ClinicalTrials.gov